Francis F Arhin Selected Research

oritavancin

1/2018	Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
10/2017	Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
2/2017	Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
1/2017	Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections.
11/2016	Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
12/2015	In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
1/2013	Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
2/2012	Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.
12/2010	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
12/2009	Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francis F Arhin Research Topics

Disease

17	Infections 01/2022 - 10/2008
4	Osteomyelitis 02/2010 - 10/2008
1	Body Weight (Weight, Body) 01/2013
1	Endocarditis 02/2012

Drug/Important Bio-Agent (IBA)

12	oritavancinIBA 01/2018 - 10/2008
7	LipoglycopeptidesIBA 01/2018 - 10/2008
7	Vancomycin FDA LinkGeneric 01/2018 - 06/2009
6	Daptomycin FDA Link 01/2018 - 06/2009
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 10/2008
4	ProdrugsIBA 02/2010 - 10/2008
3	Pharmaceutical PreparationsIBA 01/2022 - 11/2008
3	Linezolid (Zyvox)FDA Link 12/2015 - 06/2009
2	Aztreonam FDA LinkGeneric 01/2022 - 10/2021
2	avibactamIBA 01/2022 - 10/2021
2	TeicoplaninIBA 12/2009 - 06/2009
2	FluoroquinolonesIBA 11/2008 - 10/2008
1	Drug CombinationsIBA 01/2022
1	LipopeptidesIBA 01/2018
1	telavancin FDA Link 02/2017
1	dalbavancinIBA 02/2017
1	Ceftaroline FDA Link 02/2017
1	tedizolidIBA 02/2017
1	GlycopeptidesIBA 02/2010
1	Penicillins (Penicillin)FDA Link 12/2009
1	Erythromycin (Erycette)FDA LinkGeneric 12/2009
1	KRM 1648IBA 12/2008
1	Diphosphonates (Bisphosphonates)IBA 11/2008
1	EstersIBA 10/2008

Therapy/Procedure

1	Therapeutics 01/2018